What drove ALBPS.PA stock higher today?

Intraday interest pushed ALBPS.PA stock up **17.65%** to **€0.03** on 24 Mar 2026, driven by above-average volume and renewed attention on Biophytis’s clinical pipeline. No major company press release was filed during the session.

What is Meyka AI’s rating for ALBPS.PA stock?

Meyka AI rates ALBPS.PA with a score out of 100: **71.08**, Grade **B+**, Suggestion **BUY**. The grade balances benchmark and sector comparisons, growth metrics, and analyst inputs. This is informational, not investment advice.

What are key risks for ALBPS.PA stock investors?

Key risks include clinical trial outcomes, low liquidity, small market cap (**€648,138.00**), potential dilution, and weak short-term liquidity (current ratio **0.35**). These factors increase downside volatility for ALBPS.PA stock.

Does Meyka AI provide a price forecast for ALBPS.PA stock?

Yes. Meyka AI's forecast model projects **€2.98** at one year and **€1.25** at three years versus current **€0.03**. These are model projections and not guarantees; they carry high uncertainty for micro-cap biotech stocks.

EU Stocks

ALBPS.PA Biophytis S.A. EURONEXT +17.65% to €0.03 24 Mar 2026: catalysts in focus

ByHuzaifa Zahoor March 24, 2026March 24, 2026

Biophytis S.A. (ALBPS.PA) on EURONEXT jumped 17.65% intraday to €0.03 on 24 Mar 2026, driven by heavy intraday volume of 1,438,765 shares. The move follows low trading levels against a 50-day average price of €0.05 and a 200-day average of €0.11, keeping the stock volatile. We review why the ALBPS.PA stock is moving today, how fundamentals and technicals align, and what the Meyka AI forecast and grade say about upside and risk for Europe-listed small-cap biotech investors.